Purchase this article with an account.
S. Wünsch, F. Haverkamp, G. Sand, M. Fuchs, W.C. Stewart; Intraocular Pressure, Safety and Quality of Life in Glaucoma Patients Switching to Latanoprost from Adjunctive and Monotherapy Treatments . Invest. Ophthalmol. Vis. Sci. 2003;44(13):793.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate efficacy, safety and quality of life in ocular hypertensive or open-angle glaucoma patients changed to latanoprost from previous therapy. Methods: Prospective, multicenter, active controlled. Qualified patients had previous therapy substituted with latanoprost 0.005% and were followed for at least three months. Results: In 1068 patients latanoprost was persistent in 92.2% and reduced the intraocular pressure (IOP)(P < 0.001) when compared to previous monotherapies including: beta-blockers (-4.0 ± 3.7, n = 451), alpha-antagonists (-3.9 ± 3.0, n = 154), miotics (-3.8 ± 3.5, n = 21), or carbonic anhydrase inhibitors (CAI)(-3.8 ± 3.6, n = 170), and adjunctive therapy including: beta-blocker and CAI (-3.7 ± 3.1, n = 133), alpha-agonist (-3.7 ± 3.4, n = 50), or pilocarpine (-3.4 ± 3.7, n = 62), or CAI and alpha-agonist (-4.6 ± 6.4, n = 25)(P = 0.0017). The most common adverse event with latanoprost was ocular allergy (1.5% incidence). Patients showed a preference for latanoprost for many quality of life measures (P < 0.05). Conclusions: : Latanoprost generally provides reduced IOP, limited side effects and many increased quality of life measures when substituted for other common mono- and adjunctive therapies
This PDF is available to Subscribers Only